ＨＣＶ抗体陽性血液透析患者に対する鉄剤静注療法の意義

DOI PubMed 被引用文献1件 参考文献21件

書誌事項

タイトル別名
  • Significance of parenteral iron administration for HCV-positive hemodialysis patients.

この論文をさがす

抄録

Background : It is well recognized that parenteral iron administration is recommended for hemodialysis (HD) patients treated with rHuEPO. On the other hand, hepatic iron concentration increases in chronic hepatitis C, and iron reduction improves serum transaminase levels in these patients.Methods : We compared the rHuEPO doses with hematological parameters in HCV positive (n=7) and HCV-negative (n=32) HD patients when parenteral low-dose iron was administered for one year (target ferritin level : 200-300ng/ml, target hematocrit level : 30-33 %).Results : None of the parameters was significantly different between the groups at the start of the study. One year later, levels of hematocrit and serum ferritin significantly increased compared with those at the start in each group (HCV-positive group : 28.0±2.7→31.3±1.5 %, p< 0.01, 119.3±171.9→303.3±77.7 ng/ml, p<0.05, respectively, HCV-negative group : 26.8±2.2→30.0±3.5 %, p< 0.01, 69.8±100.5→278.4±66.4 ng/ml, p<0.01, respectively) . Serum transaminase levels were not significantly different between the start and end points in the HCV-positive group, but 2 patients showed an increase in these levels. In the HCV-negative group, the rHuEPO dose at the end point was significantly reduced compared with that at the start (4, 875±2, 089→4, 031±2, 203 IU/W, p<0.05). In the HCV-positive group, however, it was difficult to reduce the rHuEPO dose in order to maintain the target hematocrit level (4, 071±1, 134→3, 857±1, 464IU/W, NS).Conclusion : We suggested that rHuEPO should be used together with parenteral iron administration, even in HCV-positive HD patients, because it is safe at low doses under careful observation.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (21)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ